Boc-D-Val-OH | tert-Butoxycarbonyl-D-valine | N-protective Amino Acid

CAS No. :	22838-58-0
Formula :	C₁₀H₁₉NO₄
M.W :	217.26
SMILES Code :	CC(C)[C@@H](NC(OC(C)(C)C)=O)C(O)=O
Synonyms :	tert-Butoxycarbonyl-D-valine; N-tert-Butyloxycarbonyl-D-valine; NSC 334316
MDL No. :	MFCD00038282
InChI Key :	SZXBQTSZISFIAO-SSDOTTSWSA-N
Pubchem ID :	637605

Safety of [ 22838-58-0 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 22838-58-0 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	0
Fraction Csp3	0.8
Num. rotatable bonds	6
Num. H-bond acceptors	4.0
Num. H-bond donors	2.0
Molar Refractivity	56.47
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	75.63 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.14
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.54
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.62
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.13
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.48
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.38

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.76
Solubility	3.76 mg/ml ; 0.0173 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.74
Solubility	0.398 mg/ml ; 0.00183 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.08
Solubility	17.9 mg/ml ; 0.0824 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.53 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.71

Application In Synthesis of [ 22838-58-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 22838-58-0 ]

[ 22838-58-0 ] Synthesis Path-Downstream 1~24

1
[ 22838-58-0 ]
[ 74-88-4 ]
[ 13850-91-4 ]

Yield	Reaction Conditions	Operation in experiment
84%		To N-Boc D-valine (5 g, 11.5 mmol) at 0 C in THF (69 mL, 0.35 M) is added MeI (11.45 mL, 8 eq). NaH (60% dispersion in mineral oil, 2.76 g, 3eq) is then added carefully to the stirring solution portionwise. The mixturewas allowed to stir vigorously overnight at room temperature before beingdiluted with Et2O (70 mL) and quenched slowly with H2O (50 mL) at 0 C.The layers were separated and the aqueous layer extracted twice with Et2O(2 x 30 mL). The aqueous layer was brought to ~pH 2 with the dropwise addition of conc. HCl(checking the pH by spotting the aqueous layer onto pH paper) and extracted with EtOAc (4 x100 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, andconcentrated in vacuo. The resulting oil (4.46 g, 84% yield) was sufficiently pure for the nextstep. If desired, an analytical sample could be obtained as a white fluffy solid after flash columnchromatography (silica gel, 3%-5% MeOH/DCM). The use of only 3 eq of MeI in a similarprocedure resulted in the appearance of starting material at the end of the reaction, presumablydue to competitive precipitation of the disodium salt.3

References: [1]Organic and Biomolecular Chemistry,2016,vol. 14,p. 2090 - 2111.
[2]Helvetica Chimica Acta,2012,vol. 95,p. 973 - 982.
[3]Tetrahedron Letters,2012,vol. 53,p. 4077 - 4079.
[4]Organic and Biomolecular Chemistry,2017,vol. 15,p. 1140 - 1150.
[5]Tetrahedron,1995,vol. 51,p. 10653 - 10662.
[6]Marine Drugs,2012,vol. 10,p. 1307 - 1320.
[7]Organic and Biomolecular Chemistry,2012,vol. 10,p. 7027 - 7030.
[8]Current Medicinal Chemistry,2013,vol. 20,p. 1183 - 1194.

2
N-{3-[2-(2-hydroxy-ethoxy)-phenyl]-allyl}-acetamide [ No CAS ]
2-(benzothiazole-2-sulfonylamino)-3-(4-tert-butoxy-phenyl)-propionic acid [ No CAS ]
[ 22838-58-0 ]
[ 53308-95-5 ]
2-{2-[2-{2-[2-(3-acetylamino-propenyl)-phenoxy]-ethylamino}-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-butyrylamino}-pentanoic acid amide [ No CAS ]